SCHEMBL20918293

SCHEMBL20918293

CCOc1nc(N)ccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
NCF1 P14598 3/20 0.37
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
BACE1 P56817 3/20 0.36
CDK1 P06493 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36
MCHR1 Q99705 3/20 0.36
ADORA2A P29274 1/20 0.35
ADORA1 P30542 1/20 0.35
MAPK8 P45983 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
TLR8 Q9NR97 1/20 0.34
MBOAT4 Q96T53 1/20 0.34
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17593199 0.81 HPGD (0.42) SMN1; SMN2HPGDTDP1CDK1CDK2
SCHEMBL21223677 0.79 MBOAT4 (0.37) NCF1BACE1MBOAT4
SCHEMBL1841778 0.78 HPGD (0.43) SMN1; SMN2HPGDTSHRCDK1CDK2
SCHEMBL10758824 0.78 ALDH1A1 (0.44) SMN1; SMN2HPGDNCF1TSHRTDP1
SCHEMBL9931250 0.78 HPGD (0.43) SMN1; SMN2HPGDTDP1CDK1CDK2
SCHEMBL1256181 0.78 MCHR1 (0.40) NCF1BACE1MCHR1ALDH1A1LMNA
SCHEMBL31253174 0.78 MCHR1 (0.40) NCF1BACE1MCHR1ALDH1A1LMNA
SCHEMBL20606860 0.77 L3MBTL1 (0.39) SMN1; SMN2HPGDNCF1TSHRTDP1
SCHEMBL21223041 0.77 MBOAT4 (0.46) BACE1MCHR1ADORA2AALDH1A1MBOAT4
SCHEMBL31470137 0.74 S1PR1 (0.40) SMN1; SMN2HPGDCDK1CDK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 US disclosed
EP-3697772-A1 PYRIMIDINE TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2020-08-26 EP disclosed
CN-111247135-A Pyrimidine T-K/I-K-P inhibitor compound and application thereof 默克专利股份公司 2020-06-05 CN disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF DTYMK, TBKBP1, NFKBIA SMN1; SMN2 3978/4885HPGD 1431/4885NCF1 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.